Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-06-27 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
2025年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the resolutions passed at the 2025 second extraordinary general meeting of shareholders of 和元生物技术（上海）股份有限公司. It details the meeting date, attendance, voting results on various proposals including board elections and amendments to company governance documents. The content focuses on the voting outcomes and procedural compliance, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements. The document is about the results of shareholder votes at a general meeting, not the meeting materials or the full annual report or management information. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document length and detail support a high confidence in this classification.
2025-06-27 Chinese
和元生物技术（上海）股份有限公司2025年限制性股票激励计划（草案）之法律意见书
Regulatory Filings
2025-06-27 Chinese
关于完成董事会换届选举及聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from a company regarding the completion of the board of directors' re-election and the appointment of senior management personnel. It details the election of new board members, the appointment of the chairman and committee members, and the hiring of senior executives. The document references compliance with company law and stock exchange listing rules, and includes detailed biographies of the appointed senior management. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a proxy solicitation or voting results announcement. The content clearly focuses on changes in the company's board and senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6367 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-06-27 Chinese
和元生物技术（上海）股份有限公司2025年限制性股票激励计划首次授予的激励对象名单
Director's Dealing Classification · 95% confidence The document is a list of recipients and allocation details for a restricted stock incentive plan granted by the company's board. It includes names, positions, and stock quantities allocated under the plan. The document is an announcement related to equity incentive awards to directors, senior management, and key personnel. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but a specific announcement about stock incentives. This fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions or equity awards to company directors and executives.
2025-06-27 Chinese
关于选举第四届董事会职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new employee representative director to the company's fourth board of directors. It includes details about the election process, the term of the new board, and a biography of the elected director. There is no financial data, audit information, or report content. The document is clearly about board/management information, specifically changes in the company's board composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct announcement of a board change.
2025-06-27 Chinese
2025年第三次临时股东会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 third extraordinary shareholders' meeting (临时股东会) of 和元生物技术（上海）股份有限公司. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 3251 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is a report itself, but rather a notification about the meeting and its agenda. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-06-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.